Kivexa

Abacavir sulfate and lamivudine, the active ingredient in Kivexa, is a nucleoside reverse transcriptase inhibitor presented as a 600 mg/300 mg tablet for oral use. It treats HIV‑1 infection in adults and adolescents as part of combination antiretroviral therapy, and is approved in the European Union for treatment‑experienced patients.

GNH USA supplies Kivexa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide.

Kivexa, a nucleoside reverse transcriptase inhibitor, is used in the management of HIV infection.

- HIV‑1 infection in adults: suppresses viral replication as part of combination antiretroviral therapy. - HIV‑1 infection in adolescents: provides viral load reduction when combined with other antiretrovirals. - Treatment‑experienced patients: offers an alternative backbone regimen for those with prior therapy.

Kivexa may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea - Rash - Insomnia

Serious or Rare Side Effects: - Hypersensitivity reaction (fever, rash, organ involvement) - Severe liver injury - Lactic acidosis - Stevens‑Johnson syndrome

When prescribing Kivexa, several safety considerations should be observed.

- HLA‑B*57:01 screening: test patients before initiating therapy to avoid abacavir hypersensitivity. - Liver function monitoring: assess hepatic enzymes regularly during treatment. - Renal function monitoring: evaluate kidney function, especially in patients with pre‑existing impairment. - Pregnancy counseling: discuss unknown safety profile and weigh risks versus benefits. - Drug interactions review: check concomitant medications for potential additive toxicity. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Kivexa can interact with other medicines, requiring attention to avoid adverse effects.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of severe toxicity. - Stavudine: avoid combined use due to additive mitochondrial toxicity. - High‑dose nucleoside analogues: may increase mitochondrial toxicity when used together.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may raise plasma levels of abacavir. - Non‑nucleoside reverse transcriptase inhibitors (e.g., efavirenz): may affect lamivudine metabolism. - Alcohol: can exacerbate hepatic side effects. - Live vaccines: consider reduced efficacy or increased risk.